Results 61 to 70 of about 23,896 (206)

Mepolizumab, quality of life, and severe eosinophilic asthma [PDF]

The Lancet Respiratory Medicine, 2017
It is now ten years since the publication of the first clinical trial, eight years since the first key proof of concept studies in a population selected on the basis of inflammatory pattern and two years since approval of Mepolizumab as a treatment for severe eosinophilic asthma.
openaire   +3 more sources

Recent Developments in Monoclonal-Antibody-Based Biologic Therapy for Severe Refractory Eosinophilic Asthma

Antibodies
Background: Asthma exhibits marked heterogeneity both clinically and at the molecular phenotypic level, requiring specifically targeted treatments to block the key pathways of the disease.
Garry M. Walsh
doaj   +1 more source

Effectiveness of mepolizumab in patients with severe eosinophilic asthma: results from real-world clinical practice in Finland [PDF]

, 2022
Ville Koistinen, Paula Kauppi, J Idänpään-Heikkilä, Lauri Veijalainen, Ilona Iso‐Mustajärvi, Tero Ylisaukko‐oja, Juha Mehtälä, Arja Viinanen, Maritta Kilpeläinen   +8 more
openalex   +1 more source

Differences in Type 2 Phenotype and Clinical Characteristics of Adult Asthma Patients with Different Severity, Across GINA Step 1 to 5 Asthma

Journal of Asthma and Allergy
Wang Chun Kwok, Julie Kwan Ling Wang, Terence Chi Chun Tam, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip Department of Medicine, the University of Hong Kong, Hong Kong, SAR, People’s Republic of ChinaCorrespondence: Mary Sau Man Ip ...
Kwok WC, Wang JKL, Tam TCC, Ho JCM, Lam DCL, Ip MSM   +5 more
doaj  

Combined biologic therapy targeting B cells and eosinophils in relapsing multiple sclerosis and severe asthma: a case report of ofatumumab and mepolizumab

Frontiers in Immunology
The management of multiple sclerosis (MS) in patients with significant comorbidities such as severe asthma presents unique therapeutic challenges. We report a case of successful combined biologic therapy with ofatumumab and mepolizumab in a patient with ...
Aurora Zanghì, Paola Sofia Di Filippo, Claudia Rutigliano, Carlo Avolio, Emanuele D’Amico   +4 more
doaj   +1 more source

Association of blood inflammatory phenotypes and asthma burden in children with moderate-to-severe asthma

ERJ Open Research
Background Underlying immunological mechanisms in children with moderate-to-severe asthma are complex and unclear. We aimed to investigate the association between blood inflammatory parameters and asthma burden in children with moderate-to-severe asthma.
Amir Hossein Alizadeh Bahmani, Susanne J.H. Vijverberg, Simone Hashimoto, Christine Wolff, Catarina Almqvist, Lizan D. Bloemsma, Susanne Brandstetter, Paula Corcuera-Elosegui, Mario Gorenjak, Susanne Harner, Anna M. Hedman, Michael Kabesch, Leyre López-Fernández, Aletta D. Kraneveld, Anne H. Neerincx, Maria Pino-Yanes, Uroš Potočnik, Olaia Sardón-Prado, Barbara S. Dierdorp, Tamara Dekker, Nariman K.A. Metwally, Jan Willem Duitman, René Lutter, Paul Brinkman, Mahmoud I. Abdel-Aziz, Anke H. Maitland-van der Zee   +25 more
doaj   +1 more source

Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma

Therapeutic Advances in Respiratory Disease, 2015
Two recent phase III trials in patients with severe eosinophilic asthma have shown that anti-interleukin 5 (IL-5) therapy with mepolizumab reduces the frequency of asthma attacks, improves symptoms and allows patients to reduce oral glucocorticoid use ...
Bart Hilvering, Luzheng Xue, Ian D. Pavord   +2 more
doaj   +1 more source

Use of FeNO to Predict Anti-IL-5 and IL-5R Biologics Efficacy in a Real-World Cohort of Adults with Severe Eosinophilic Asthma

, 2022
Charlotte Ménigoz, S. Dirou, Arnaud Chambellan, Dorian Hassoun, Antoine Moui, A. Magnan, F.–X. Blanc   +6 more
openalex   +1 more source

Severe Asthma or Chronic Obstructive Pulmonary Disease with Eosinophilic Inflammation? From Uncertainty to Remission under Anti IL-5R Therapy

Medicina
Background and Objectives: Severe adult-onset eosinophilic asthma and COPD with eosinophilic inflammation are two entities with a similar clinical course and are sometimes difficult to differentiate in clinical practice, especially in patients with a ...
Bianca Oprescu, Oana Raduna, Stefan Mihaicuta, Stefan Frent   +3 more
doaj   +1 more source

Clinical Outcomes and Health-Care Resource Use Associated With Reslizumab Treatment in Adults With Severe Eosinophilic Asthma in Real-World Practice

, 2020
Michael E. Wechsler, Stephen P. Peters, Tanisha Hill, Rinat Ariely, Michael DePietro, Maurice T. Driessen, Emi Terasawa, Darren Thomason, Reynold A. Panettieri   +8 more
openalex   +2 more sources